HBOT for Radiation Cystitis and Proctitis: What the Randomized Trials Show

Pelvic radiation can damage the bladder and bowel years after cancer treatment ends. Hyperbaric oxygen therapy (HBOT) is one of the few treatments studied in randomized trials for this problem, and it is a recognized use of HBOT for late radiation tissue injury. The results are real but uneven, so it helps to look at what the trials actually found.

This page walks through the condition, how HBOT is supposed to help, and what the randomized controlled trials (RCTs) and Cochrane review show. The goal is a sober read of the evidence, not a sales pitch.

What radiation cystitis and proctitis are

Radiation is a core tool for treating cancers of the prostate, cervix, bladder, rectum, and other pelvic organs. It saves lives. But the same radiation that kills tumor cells can also injure nearby healthy tissue.

When that injury shows up months or years later, doctors call it late radiation tissue injury (LRTI). Two of the most common forms involve the bladder and bowel.

• Radiation cystitis is injury to the bladder lining. The worst form, hemorrhagic cystitis, causes blood in the urine, painful urination, urgency, and sometimes serious bleeding that needs hospital care.
• Radiation proctitis is injury to the rectum and lower bowel. It causes rectal bleeding, pain, urgency, loose stools, and leakage.

These problems can start 6 months to many years after treatment. They tend to be chronic. They are driven by damage to small blood vessels, scarring, and poor blood supply in the irradiated tissue.

Standard care comes first. For the bladder, that can mean bladder irrigation, medications, and procedures to stop bleeding. For the bowel, that can include topical treatments, sucralfate enemas, and a procedure called argon plasma coagulation to seal bleeding spots. HBOT enters the picture when these standard steps do not control the symptoms.

Why this injury is so stubborn

Radiation injury is not like a normal cut that heals and moves on. The damage builds slowly. Radiation harms the small blood vessels in the treated area, a process doctors call endarteritis obliterans. Over months and years, those vessels narrow and close off. The tissue they once fed becomes hypoxic, meaning starved of oxygen.

Hypoxic tissue cannot heal well. It scars instead of repairing. Blood vessels that should grow back do not. The result is a tissue bed that is, in the words of researchers, hypoxic, hypocellular, and hypovascular: low on oxygen, low on cells, and low on blood supply. That is why radiation cystitis and proctitis can drag on for years and resist ordinary treatment. The underlying tissue simply cannot mount a normal healing response.

This is the exact problem HBOT is built to attack. Whether it succeeds is the question the trials try to answer.

How HBOT is supposed to help

In an HBOT session, you breathe near-100% oxygen inside a pressurized chamber. The pressure is set above normal sea-level pressure, usually around 2.0 to 2.5 atmospheres absolute (ATA). For more on how pressure levels work, see our guide on HBOT pressure explained.

The core problem in radiation injury is a tissue bed starved of blood and oxygen. The theory behind HBOT targets that directly:

• Higher oxygen in damaged tissue. Breathing oxygen under pressure dissolves far more oxygen into the blood plasma, pushing oxygen into tissue that the radiation-damaged vessels can no longer supply well.
• New blood vessel growth (angiogenesis). Repeated sessions appear to stimulate the body to grow new small blood vessels in the irradiated area, a process supported by lab and animal work.
• Better wound healing and less inflammation. More oxygen supports the cells and immune steps that repair tissue.

For a fuller breakdown of these mechanisms, see how HBOT works. The short version: the goal is to rebuild blood supply in tissue that radiation left scarred and oxygen-poor. That is a reasonable target, but a reasonable theory does not prove a treatment works. For that, you need trials.

One more wrinkle is worth understanding. The angiogenesis response is thought to be cumulative and somewhat lasting. The idea is that a full course of HBOT does not just flood the tissue with oxygen for two hours at a time. Instead, the repeated oxygen swings are thought to signal the body to lay down new capillaries that stay after treatment ends. That is the rationale for giving 30 or more sessions rather than a handful. It is also why benefits, when they happen, can show up gradually over weeks rather than overnight. This is a mechanism story supported by laboratory and animal work, and it is the biological argument for HBOT. But mechanism is not outcome, and the trials below are what actually test whether patients get better.

What the randomized trials actually show

This is the part that matters most, and it is where you should be careful. The evidence for HBOT in radiation injury is mixed. Some good trials are positive. At least one good trial is negative. Below is a summary of the strongest randomized evidence and the main systematic reviews.

The positive cystitis trial: RICH-ART

The strongest randomized evidence for the bladder comes from the RICH-ART trial (PMID 31537473), published in Lancet Oncology in 2019. This was a randomized, controlled, phase 2-3 trial of patients with radiation-induced cystitis.

Patients were assigned to HBOT plus standard care or standard care alone. The HBOT group showed a significant improvement in urinary tract symptom scores and in quality of life compared with the control group. The trial was not blinded, which is a limitation, but it is the best randomized signal we have that HBOT can help radiation cystitis symptoms.

The positive proctitis trial: Clarke 2008

For the bowel, the Clarke 2008 trial (PMID 18342453) is the landmark positive study. It was a double-blind, sham-controlled crossover trial in 120 patients with chronic refractory radiation proctitis. At the dose tested, HBOT produced a significant improvement in healing compared with sham, with benefits that held up over long-term follow-up.

This trial is important because it was blinded and sham-controlled. Patients did not know whether they were getting real HBOT or a sham (lower-pressure) exposure, which reduces the placebo effect that can otherwise inflate results. Blinding is hard to do in HBOT research because patients can sometimes sense the pressure change, but when a positive result survives a blinded design, it carries more weight than an open-label study.

A practical note on dose: Clarke 2008 also tested whether a lower number of sessions worked as well, and the higher-dose arm was where the clear healing signal appeared. That detail feeds into the wider debate about whether some negative HBOT trials simply used too few sessions or the wrong patients.

The negative proctitis trial: HOT2

Now the honest counterweight. The HOT2 trial (PMID 26703894), also published in Lancet Oncology, was a double-blind, sham-controlled phase 3 RCT in patients with chronic bowel dysfunction after pelvic radiotherapy. It found no significant benefit of HBOT over sham on the main bowel symptom measures.

Why do Clarke 2008 and HOT2 disagree? Researchers point to several possible reasons:

• Different patients. The trials enrolled people with different symptom severity and different mixes of bleeding versus other bowel problems. HOT2 included a broad range of chronic bowel dysfunction, while bleeding-dominant injury may respond differently than pain or urgency.
• Different endpoints. Clarke focused more on a clinician-graded healing score; HOT2 used patient-reported bowel symptom scales. A treatment can move one kind of measure and not another.
• Possible dose and timing differences, and the general difficulty of running clean HBOT trials.
• The sham problem. In a sham-controlled HBOT trial, the control group still gets some pressurized air, and even that mild exposure plus the ritual of daily treatment can produce real improvement. That makes it harder for the real-HBOT group to pull clearly ahead, and it may partly explain a null result like HOT2's.

None of this proves HBOT works or does not work for the bowel. It shows why a single trial, in either direction, should not be the last word.

The takeaway is not that one trial is right and one is wrong. It is that the benefit of HBOT for radiation bowel injury is uncertain and probably depends on which patients and which symptoms you measure.

What the Cochrane review concluded

The 2016 Cochrane systematic review by Bennett and colleagues (PMID 27123955) pooled the randomized trials on HBOT for late radiation tissue injury across several body sites. It found that HBOT improved certain outcomes, including healing in radiation proctitis and some bladder and head-and-neck endpoints, but it flagged that the evidence base was small, uneven, and at risk of bias. The review called for more and better trials rather than declaring the question settled.

The 2018 meta-analysis in Current Urology Reports (PMID 29654564) looked specifically at hemorrhagic cystitis and reported a high pooled rate of bleeding resolution after HBOT. But most of that data came from case series and cohort studies, not RCTs, so it carries less weight than RICH-ART.

You can browse the full literature yourself with this PubMed search for HBOT and late radiation tissue injury. For our broader look at the whole category, see the HBOT for late radiation tissue injury evidence atlas and our oncology-focused radiation tissue damage review.

Reading the evidence honestly

Put together, here is a fair summary of where things stand:

• Radiation cystitis: One positive RCT (RICH-ART) plus supportive but lower-quality data. This is among the better-supported uses of HBOT in radiation injury, though more blinded trials would strengthen the case.
• Radiation proctitis and bowel injury: Genuinely mixed. One positive blinded trial (Clarke 2008) and one negative blinded trial (HOT2). The benefit, if present, is modest and patient-dependent.
• Overall: HBOT can help some patients with severe, treatment-resistant radiation injury of the bladder and bowel. It is not a guaranteed fix, and it is not first-line care.

That nuance matters. A treatment can be a reasonable option for a select group of patients while still having an evidence base that is far from airtight. Both things are true here.

How to weigh it for yourself

If you or a loved one is considering HBOT for radiation injury, a few questions help cut through the marketing:

• Has standard care really been tried? HBOT is for refractory cases. If first-line treatments have not been fully used, those usually come first.
• Which symptom are you treating? The cystitis evidence is somewhat stronger than the bowel evidence. Bleeding tends to respond better than vague pain or urgency.
• Can you commit to a full course? A few sessions are unlikely to do much. The trials that worked used 30 or more.
• Is the facility accredited and physician-supervised? Radiation injury is a medical indication, not a wellness add-on. It belongs in a real hyperbaric program tied to your cancer-care team.

A treatment with mixed evidence is not the same as a treatment with no evidence. For severe, bleeding radiation cystitis that has not responded to anything else, the randomized data give a fair reason to try HBOT. For mild bowel symptoms, the case is weaker, and the burden of daily treatment may not be worth it. Reasonable doctors land in different places, and your own situation drives the call.

Typical protocol

HBOT for radiation injury is a course of treatment, not a one-off. Based on the trial protocols and clinical practice, a typical plan looks like this:

That is a major time commitment, often 6 to 8 weeks of near-daily visits. Patients should understand that scale before starting.

What a session is like

Each session follows a similar rhythm. You enter the chamber, which is either a clear tube for one person (monoplace) or a larger room shared with others (multiplace). The chamber is slowly pressurized. During this part, your ears feel pressure, much like a plane taking off, and staff coach you on how to clear them by swallowing or yawning.

Once at depth, you breathe the oxygen and relax. Many patients read, watch a screen, or nap. At the end, the chamber slowly depressurizes. The whole visit, including pressurization and exit, runs around two hours. Then you do it again the next day.

The repetition is the hard part for many patients. Daily trips to a hyperbaric facility for weeks demand time off work, transportation, and stamina. That burden is a real factor in deciding whether HBOT makes sense for a given person.

Safety and side effects

HBOT has a good overall safety record when run by trained staff in an accredited facility, but it is not risk-free. Knowing the possible side effects helps set honest expectations.

• Ear and sinus pressure. The most common complaint. The pressure change can cause ear pain or, less often, eardrum injury. Learning to clear your ears reduces this.
• Temporary vision changes. Some patients become more nearsighted over a long course. This usually reverses in the weeks after treatment ends.
• Confinement discomfort. Being in a closed chamber can feel claustrophobic for some people. Staff can help, and many adjust after the first few sessions.
• Oxygen toxicity (rare). Breathing high-pressure oxygen can, rarely, trigger a seizure. Facilities use protocols and air breaks to keep this risk low.
• Fire risk. Pure oxygen feeds fire, which is why facilities ban lighters, certain cosmetics, and synthetic fabrics. The FDA has stressed safe-use rules for exactly this reason.

People with certain untreated lung conditions, recent ear surgery, or specific medical issues may not be candidates. This is why a physician evaluation comes first.

Who qualifies

HBOT for radiation injury is generally considered for people who:

• Have confirmed late radiation injury of the bladder or bowel (not the early, temporary reaction during treatment).
• Have symptoms that persist despite standard care such as medications, irrigation, or procedures.
• Do not have a condition that makes HBOT unsafe, such as certain untreated lung problems.

Cancer history needs careful discussion with your oncology team before starting HBOT. Your physician decides whether you are a candidate. For a general overview, see our HBOT candidate eligibility guide.

HBOT is an adjunct, not a standalone cure

This point is important enough to state plainly. In every major trial, HBOT was tested on top of standard care, not instead of it. The trial groups still received the usual urology or gastroenterology treatment. HBOT was an add-on for tissue that had not responded.

So HBOT is an adjunct therapy for radiation cystitis and proctitis. It is not a replacement for the procedures, medications, and monitoring your specialists provide. Anyone presenting HBOT as a standalone cure for radiation injury is going beyond the evidence.

FDA and UHMS status

Late radiation tissue injury, including radiation cystitis and proctitis, is a recognized indication for hyperbaric oxygen therapy.

• The Undersea and Hyperbaric Medical Society (UHMS) lists delayed radiation injury (soft tissue and bony necrosis) among its approved indications. See the UHMS indications page.
• The FDA recognizes radiation tissue injury among the conditions HBOT devices are cleared to treat, and it stresses that HBOT should be used under a doctor's care in an accredited facility. See the FDA letter to health care providers on safe HBOT use.
• Medicare covers HBOT for several conditions under National Coverage Determination 20.29, and many plans cover radiation injury when standard care has failed. Coverage rules and prior authorization vary.

For how coverage works across the approved conditions, see our guide to HBOT insurance coverage and the approved indications.

Frequently Asked Questions

Does HBOT cure radiation cystitis?

No treatment is guaranteed. The RICH-ART randomized trial found that HBOT improved urinary symptoms and quality of life in radiation cystitis, and other studies report high rates of stopped bleeding. But the data is limited and HBOT is used as an add-on to standard care, not a standalone cure. Think of it as a reasonable option for stubborn cases, not a sure thing.

Why do the proctitis trials disagree?

The Clarke 2008 trial found a benefit for radiation proctitis, while the HOT2 trial found none. They enrolled different patients, measured different outcomes (clinician-graded healing versus patient-reported bowel symptoms), and likely differed in dose and timing. The honest reading is that benefit for bowel injury is uncertain and probably depends on the specific patient and symptom.

How many HBOT sessions are needed for radiation injury?

Most protocols run about 30 to 40 sessions, sometimes up to 60. Sessions are usually daily, five days a week, at around 2.0 to 2.5 ATA for 90 to 120 minutes each. That often means 6 to 8 weeks of near-daily treatment, so it is a real commitment.

Is HBOT covered by insurance for radiation cystitis or proctitis?

Often, yes, when standard care has failed first. Radiation tissue injury is a recognized indication, and Medicare covers HBOT for qualifying conditions under NCD 20.29. Coverage details and prior-authorization rules vary by plan, so confirm with your insurer and provider before starting.

Is HBOT used instead of other radiation injury treatments?

No. In all the major trials, HBOT was added on top of standard urology or gastroenterology care, not used in its place. It is an adjunct therapy for tissue that has not responded to first-line treatment, not a replacement for those treatments.

Medical disclaimer

This article is for general information only and is not medical advice; talk to your physician or oncology team before considering hyperbaric oxygen therapy for any radiation injury.